Major Developments in the Design of Inhibitors along the Kynurenine Pathway

Author(s): Kelly R. Jacobs, Gloria Castellano-Gonzalez, Gilles J. Guillemin*, David B. Lovejoy*

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 23 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Disrupted kynurenine pathway (KP) metabolism has been implicated in the progression of neurodegenerative disease, psychiatric disorders and cancer. Modulation of enzyme activity along this pathway may therefore offer potential new therapeutic strategies for these conditions. Considering their prominent positions in the KP, the enzymes indoleamine 2,3-dioxygenase, kynurenine 3-monooxygenase and kynurenine aminotransferase, appear the most attractive targets. Already, increasing interest in this pathway has led to the identification of a number of potent and selective enzyme inhibitors with promising pre-clinical data and the elucidation of several enzyme crystal structures provides scope to rationalize the molecular mechanisms of inhibitor activity. The field seems poised to yield one or more inhibitors that should find clinical utility.

Keywords: Kynurenine pathway, neurodegeneration, cancer, indoleamine 2, 3-dioxygenase, kynurenine 3- monooxygenase, enzyme inhibitors.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 11 September, 2017
Page: [2471 - 2495]
Pages: 25
DOI: 10.2174/0929867324666170502123114

Article Metrics

PDF: 72
HTML: 11
PRC: 1